Stefania Fasano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4165718/publications.pdf

Version: 2024-02-01

279798 477307 2,457 30 23 29 citations h-index g-index papers 34 34 34 3257 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	RGS4 negatively modulates Nociceptin/Orphanin FQ opioid receptor signaling: implication for Lâ€Dopaâ€induced dyskinesia British Journal of Pharmacology, 2021, , .	5.4	1
2	The Inhibition of RasGRF2, But Not RasGRF1, Alters Cocaine Reward in Mice. Journal of Neuroscience, 2019, 39, 6325-6338.	3.6	9
3	Antiâ€Parkinsonian and antiâ€dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists. British Journal of Pharmacology, 2018, 175, 782-796.	5. 4	16
4	Genetic enhancement of Ras-ERK pathway does not aggravate L-DOPA-induced dyskinesia in mice but prevents the decrease induced by lovastatin. Scientific Reports, 2018, 8, 15381.	3.3	11
5	Severe Intellectual Disability and Enhanced Gamma-Aminobutyric Acidergic Synaptogenesis in a Novel Model of Rare RASopathies. Biological Psychiatry, 2017, 81, 179-192.	1.3	30
6	Impairment of cocaine-mediated behaviours in mice by clinically relevant Ras-ERK inhibitors. ELife, 2016, 5, .	6.0	35
7	Differential involvement of Rasâ€GRF1 and Rasâ€GRF2 in Lâ€DOPAâ€induced dyskinesia. Annals of Clinical and Translational Neurology, 2015, 2, 662-678.	3.7	19
8	Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Progress in Neurobiology, 2015, 132, 96-168.	5.7	379
9	Derangement of Ras-Guanine Nucleotide-Releasing Factor 1 (Ras-GRF1) and Extracellular Signal-Regulated Kinase (ERK) Dependent Striatal Plasticity in L-DOPA-Induced Dyskinesia. Biological Psychiatry, 2015, 77, 106-115.	1.3	67
10	Behavioral Methods for the Study of the Ras–ERK Pathway in Memory Formation and Consolidation: Passive Avoidance and Novel Object Recognition Tests. Methods in Molecular Biology, 2014, 1120, 131-156.	0.9	29
11	Levodopa gains psychostimulantâ€like properties after nigral dopaminergic loss. Annals of Neurology, 2013, 74, 140-144.	5.3	43
12	l-DOPA Impairs Proteasome Activity in Parkinsonism through D ₁ Dopamine Receptor. Journal of Neuroscience, 2012, 32, 681-691.	3.6	37
13	Nociceptin/Orphanin FQ Receptor Agonists Attenuate L-DOPA-Induced Dyskinesias. Journal of Neuroscience, 2012, 32, 16106-16119.	3.6	39
14	MicelackingRas- GRF1 showcontextualfearcondition- ing butnotspatialmemoryimpair-ments:convergentevidencefromtwo independentlygeneratedmousemutant lines. Frontiers in Behavioral Neuroscience, 2011, 5, 78.	2.0	27
15	Ras?ERK Signaling in Behavior: Old Questions and New Perspectives. Frontiers in Behavioral Neuroscience, 2011, 5, 79.	2.0	51
16	Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with ⟨scp⟩ ⟨ scp⟩ -dopaâ€"induced dyskinesia. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 21824-21829.	7.1	141
17	Inhibition of CREB activity in the dorsal portion of the striatum potentiates behavioral responses to drugs of abuse. Frontiers in Behavioral Neuroscience, 2009, 3, 29.	2.0	27
18	Ras-Guanine Nucleotide-Releasing Factor 1 (Ras-GRF1) Controls Activation of Extracellular Signal-Regulated Kinase (ERK) Signaling in the Striatum and Long-Term Behavioral Responses to Cocaine. Biological Psychiatry, 2009, 66, 758-768.	1.3	96

#	Article	IF	CITATION
19	Multipotential Neural Precursors Transplanted into the Metachromatic Leukodystrophy Brain Fail to Generate Oligodendrocytes but Contribute to Limit Brain Dysfunction. Developmental Neuroscience, 2008, 30, 340-357.	2.0	43
20	Safety of Arylsulfatase A Overexpression for Gene Therapy of Metachromatic Leukodystrophy. Human Gene Therapy, 2007, 18, 821-836.	2.7	47
21	Cerebellar Neurons and Glial Cells Are Transducible by Lentiviral Vectors without Decrease of Cerebellar Functions. Developmental Neuroscience, 2006, 28, 216-221.	2.0	20
22	Knockout of ERK1 Enhances Cocaine-Evoked Immediate Early Gene Expression and Behavioral Plasticity. Neuropsychopharmacology, 2006, 31, 2660-2668.	5.4	101
23	Impaired Bidirectional Synaptic Plasticity and Procedural Memory Formation in Striatum-Specific cAMP Response Element-Binding Protein-Deficient Mice. Journal of Neuroscience, 2006, 26, 2808-2813.	3.6	93
24	Oligodendroglial Progenitor Cell Therapy Limits Central Neurological Deficits in Mice with Metachromatic Leukodystrophy. Journal of Neuroscience, 2006, 26, 3109-3119.	3.6	60
25	891. Correction of Established Neurologic Disease and Evidences of In Vivo Cross Correction in the Mouse Model of Metachromatic Leukodystrophy. Molecular Therapy, 2006, 13, S343.	8.2	0
26	Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. Journal of Clinical Investigation, 2006, 116 , $3070-3082$.	8.2	197
27	Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. Journal of Clinical Investigation, 2004, 113, 1118-1129.	8.2	117
28	Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. Journal of Clinical Investigation, 2004, 113, 1118-1129.	8.2	256
29	Cellular Mechanisms of Striatum-Dependent Behavioral Plasticity and Drug Addiction. Current Molecular Medicine, 2002, 2, 649-665.	1.3	45
30	Knockout of ERK1 MAP Kinase Enhances Synaptic Plasticity in the Striatum and Facilitates Striatal-Mediated Learning and Memory. Neuron, 2002, 34, 807-820.	8.1	420